Related Experiment Video
Updated: Feb 19, 2026
Evaluation of Stem Cell Therapies in a Bilateral Patellar Tendon Injury Model in Rats
Published on: March 30, 2018
Mesenchymal Stem Cells Contribute to Improvement of Renal Function in a Canine Kidney Injury Model
Seung-Jun Lee1, Min-Ok Ryu1, Min-Soo Seo2
1Department of Internal Veterinary Medicine, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea.
Background/Aim:
The kidney excretes waste materials and regulates important metabolic functions, and renal disorders constitute a significant medical problem and can result in fatalities. In the present study, mesenchymal stem cells derived from canine umbilical cord blood (cUCB-MSCs) were isolated and evaluated for their ability to improve renal function in a canine model of acute kidney injury (AKI).
Materials And Methods:
The canine AKI model was developed by i.v. injection of cisplatin and gentamycin into 14 male beagle dogs. cUCB-MSCs were administered into the renal corticomedullary junction following AKI induction. Survival time, clinical signs, blood analysis and histological parameters were analyzed.
Results:
The group treated with AKI plus cUCB-MSCs had decreased blood urea nitrogen and creatinine levels, and showed an extended life-span and improved histological manifestations. MSCs were detected around the tubules of these kidneys at the histological level.
Conclusion:
Taken together, our findings suggest that cUCB-MSCs could be an alternative therapeutic agent for canine AKI.
Insights
Canine umbilical cord blood mesenchymal stem cells (cUCB-MSCs) show promise in treating acute kidney injury (AKI) in dogs. Treatment with cUCB-MSCs improved kidney function markers and survival rates in a canine AKI model.
Area of Science:
- Veterinary Medicine
- Regenerative Medicine
- Nephrology
Background:
- Renal disorders pose significant health risks, including fatalities.
- Acute kidney injury (AKI) is a critical condition requiring effective therapeutic strategies.
- Mesenchymal stem cells (MSCs) are being investigated for their regenerative potential in various medical fields.
Purpose of the Study:
- To evaluate the therapeutic efficacy of canine umbilical cord blood-derived mesenchymal stem cells (cUCB-MSCs) in a canine model of acute kidney injury (AKI).
- To assess the impact of cUCB-MSC transplantation on renal function, survival, and histological parameters in dogs with AKI.
Main Methods:
- An experimental canine AKI model was established using intravenous injection of cisplatin and gentamicin in 14 male beagle dogs.
- cUCB-MSCs were administered to the renal corticomedullary junction following AKI induction.
- Survival time, clinical signs, blood analysis (blood urea nitrogen, creatinine), and histological parameters were analyzed to assess treatment outcomes.
Main Results:
- Dogs treated with cUCB-MSCs exhibited reduced blood urea nitrogen and creatinine levels, indicating improved kidney function.
- The cUCB-MSC treated group demonstrated an extended lifespan and improved histological manifestations compared to the untreated AKI group.
- Histological examination confirmed the presence of MSCs around the renal tubules in the treated kidneys.
Conclusions:
- Canine umbilical cord blood-derived mesenchymal stem cells (cUCB-MSCs) show potential as a therapeutic agent for canine acute kidney injury (AKI).
- These findings suggest that cUCB-MSCs can ameliorate renal damage and improve outcomes in a canine model of AKI.
- cUCB-MSCs represent a promising alternative treatment for dogs suffering from kidney disorders.
